Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps

40Citations
Citations of this article
53Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Abstract: Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have different age-specific characteristics and definitions. Trials on surfactant for ARDS in children and neonates have been performed well before the PARDS and NARDS definitions and yielded conflicting results. This is mainly due to heterogeneity in study design reflecting historic lack of pathobiology knowledge. We reviewed the available clinical and preclinical data to create an expert consensus aiming to inform future research steps and advance the knowledge in this area. Eight trials investigated the use of surfactant for ARDS in children and ten in neonates, respectively. There were improvements in oxygenation (7/8 trials in children, 7/10 in neonates) and mortality (3/8 trials in children, 1/10 in neonates) improved. Trials were heterogeneous for patients’ characteristics, surfactant type and administration strategy. Key pathobiological concepts were missed in study design. Consensus with strong agreement was reached on four statements:1.There are sufficient preclinical and clinical data to support targeted research on surfactant therapies for PARDS and NARDS. Studies should be performed according to the currently available definitions and considering recent pathobiology knowledge.2.PARDS and NARDS should be considered as syndromes and should be pre-clinically studied according to key characteristics, such as direct or indirect (primary or secondary) nature, clinical severity, infectious or non-infectious origin or patients’ age.3.Explanatory should be preferred over pragmatic design for future trials on PARDS and NARDS.4.Different clinical outcomes need to be chosen for PARDS and NARDS, according to the trial phase and design, trigger type, severity class and/or surfactant treatment policy. We advocate for further well-designed preclinical and clinical studies to investigate the use of surfactant for PARDS and NARDS following these principles.[Figure not available: see fulltext.]

References Powered by Scopus

Acute respiratory distress syndrome: The Berlin definition

8854Citations
N/AReaders
Get full text

Acute respiratory distress in adults.

3172Citations
N/AReaders
Get full text

Subphenotypes in acute respiratory distress syndrome: Latent class analysis of data from two randomised controlled trials

1150Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Non-ionic surfactants for stabilization of polymeric nanoparticles for biomedical uses

191Citations
N/AReaders
Get full text

Epidemiology of Neonatal Acute Respiratory Distress Syndrome: Prospective, Multicenter, International Cohort Study

60Citations
N/AReaders
Get full text

A recipe for a good clinical pulmonary surfactant

32Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

De Luca, D., Cogo, P., Kneyber, M. C., Biban, P., Semple, M. G., Perez-Gil, J., … Rimensberger, P. C. (2021, December 1). Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps. Critical Care. BioMed Central Ltd. https://doi.org/10.1186/s13054-021-03489-6

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

48%

Researcher 8

35%

Professor / Associate Prof. 3

13%

Lecturer / Post doc 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 16

67%

Nursing and Health Professions 5

21%

Pharmacology, Toxicology and Pharmaceut... 2

8%

Chemical Engineering 1

4%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 44

Save time finding and organizing research with Mendeley

Sign up for free